Gemcitabine+Paclitaxel (anthras pre-treated)
•
International phase III RCT: paclitaxel
175
/gemcitabine
1250
vs paclitaxel
175
q21d
–
Relapsed after adjuvant anthras (N=266) & any prior chemotherapy for MBC was not allowed
•
Primary endpoint: OS (secondary: TTP, RR, PFS, DoR, toxicity)
Albain et al JCO 2008
•
more G3/4 neutropenia on GT and G2-
4 fatigue and neuropathy were slightly
more prevalent on GT
•
The results establish GT as a reasonable choice for women who require cytoreduction with
manageable toxicities
